Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 20, Issue 10, Pages 664-677
Publisher
Springer Science and Business Media LLC
Online
2023-07-24
DOI
10.1038/s41571-023-00794-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
- (2023) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.
- (2023) Clemens Aigner et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.
- (2023) Jonathan Spicer et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.
- (2023) Shun Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
- (2023) Keiju Aokage et al. JOURNAL OF CLINICAL ONCOLOGY
- 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
- (2023) D.P. Carbone et al. Journal of Thoracic Oncology
- 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
- (2023) P.M. Forde et al. Journal of Thoracic Oncology
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
- (2023) Tina Cascone et al. NATURE MEDICINE
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- (2023) Sapna P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- (2023) Heather Wakelee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
- (2023) Masahiro Tsuboi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- (2023) Mariano Provencio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-small-cell Lung Cancer
- (2022) Peng Zhang et al. ANNALS OF THORACIC SURGERY
- First-Line Immunotherapy for Non–Small-Cell Lung Cancer
- (2022) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2022) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
- (2022) Howard Jack West et al. Journal for ImmunoTherapy of Cancer
- VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
- (2022) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
- (2022) Fan Zhang et al. Journal of Thoracic Oncology
- Perioperative targeted therapy for oncogene-driven NSCLC
- (2022) Si-Yang Liu et al. LUNG CANCER
- Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
- (2022) Edward S. Kim et al. NATURE MEDICINE
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
- (2022) Jia-Tao Zhang et al. Cancer Discovery
- Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
- (2022) Kenneth L. Kehl et al. JAMA Oncology
- Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
- (2022) Hiroaki Akamatsu et al. CLINICAL CANCER RESEARCH
- EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
- (2022) Mary E.R. O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.
- (2022) Fuming Qiu et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
- (2022) Samuel Rosner et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
- (2022) Mariano Provencio et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
- (2022) Karen L. Reckamp et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- (2022) Jeanne Tie et al. NEW ENGLAND JOURNAL OF MEDICINE
- 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
- (2022) G. Zalcman et al. ANNALS OF ONCOLOGY
- LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
- (2022) E.B. Garon et al. ANNALS OF ONCOLOGY
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227
- (2022) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Results of the Lung Cancer Mutation Consortium 3 (LCMC 3) Trial:
- (2022) Valerie W. Rusch et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
- (2022) H. Wakelee et al. Journal of Thoracic Oncology
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
- (2022) D. Rodriguez-Abreu et al. Journal of Thoracic Oncology
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
- (2022) Jamie E. Chaft et al. NATURE MEDICINE
- Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
- (2022) Marie Wislez et al. Journal for ImmunoTherapy of Cancer
- LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
- (2022) T.S.K. Mok et al. ANNALS OF ONCOLOGY
- Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma
- (2022) Bharathi Muthusamy et al. Journal of Thoracic Oncology
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
- (2021) Nasser K Altorki et al. LANCET ONCOLOGY
- Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
- (2021) Jamie E. Chaft et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
- (2021) E. Felip et al. ANNALS OF ONCOLOGY
- Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
- (2021) Xabier Mielgo-Rubio et al. Future Oncology
- SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
- (2021) Sacha I. Rothschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.
- (2021) Sanja Dacic et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
- (2021) Dean F. Bajorin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
- (2021) Toon Allaeys et al. Cancers
- 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
- (2021) C. Zhou et al. ANNALS OF ONCOLOGY
- 1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
- (2021) M.G. Kris et al. ANNALS OF ONCOLOGY
- Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
- (2021) Liang Xia et al. CLINICAL CANCER RESEARCH
- Surgery without preoperative histological confirmation of lung cancer: what is the current clinical practice?
- (2021) Mohammad R. Ghamati et al. Journal of Thoracic Disease
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Harnessing cancer immunotherapy during the unexploited immediate perioperative period
- (2020) Pini Matzner et al. Nature Reviews Clinical Oncology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model
- (2020) Asunción Martín-Ruiz et al. Scientific Reports
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- (2020) Barzin Y. Nabet et al. CELL
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- (2020) David M. Waterhouse et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
- (2020) Siddharth Sheth et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
- (2020) Joshua E Reuss et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Current status of immune checkpoint inhibition in early-stage NSCLC
- (2019) J Vansteenkiste et al. ANNALS OF ONCOLOGY
- Perioperative dynamic changes in circulating tumor DNA in lung cancer patients (DYNAMIC)
- (2019) Kezhong Chen et al. CLINICAL CANCER RESEARCH
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer
- (2018) Tina Cascone et al. CANCER RESEARCH
- Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
- (2018) Orneala Bakos et al. Journal for ImmunoTherapy of Cancer
- Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
- (2018) Valsamo Anagnostou et al. CANCER RESEARCH
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non–Small-Cell Lung Cancer
- (2013) Wei-Yu Liao et al. Clinical Lung Cancer
- Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials
- (2012) Guillaume Mouillet et al. Journal of Thoracic Oncology
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started